Worldwide clinical data on efficacy and safety of XXXX .

@entity1 @entity2954 @entity295 @entity2177 @entity344 @entity693 @entity79 @entity5280 @entity1320 @entity2259
During the clinical trials 8,861 @entity1 have been treated with @entity2177 worldwide. 3,822 of the therapeutic courses were valid for analysis of efficacy according to FDA standards. The following dosages were usually administered: UTI: 100 to 500 mg twice daily orally or 100 mg twice daily intravenously; RTI: 250 to 1000 mg twice daily orally or 200 mg twice daily intravenously; @entity295 : 200 mg intravenously twice daily; @entity2954 : 250 to 500 mg single tablet orally; all other infections: 500 to 1000 mg twice daily orally or 200 mg twice daily intravenously. @entity2177 was administered to 762 courses of lower RTI, 88 courses of upper RTI, 108 courses of @entity2259 , 766 courses of skin structure infection, 142 courses of @entity79 , 149 courses of @entity1320 , 33 courses of @entity344 , 1,633 courses of UTI, 49 courses of @entity5280 , 279 courses of STD, mainly @entity2954 , and three courses of @entity693 . The clinical response was resolution in 76%, improvement in 18% and failure in only 6%. Bacteriologic response by all sites evaluable: pathogens were eradicated from 74%, markedly reduced in 2%, persisted in 10%. Relapse occurred in 4% and reinfection was observed in another 6%. The overall response was favourable for 90% of the @entity1 . Drug safety was established on a data base of 8,861 courses worldwide. The following side-effects according to COSTART terminology were observed: digestive 5%, metabolic nutritional 4.6%, central nervous 1.6%, skin 1.4%, hemic and lymphatic 1%, cardiovascular 0.4%, body as a whole 0.4%, urogenital 0.3%, special senses 0.3%, musculo-skeletal 0.1%, respiratory 0.08%. Several courses had more than one reaction. Thus the total incidence of side-effects for the treated @entity1 population was 10.2%. @entity2177 is a highly effective drug and a breakthrough in several areas of medical interest. It is relatively safe and side-effects are usually mild or moderate in intensity and transient.
